In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 1.26 a new company low.

Within Major Pharmaceutical Preparations industry 333 other companies have achieved higher Quick Ratio than Vertex Pharmaceuticals Inc in third quarter 2026. While Quick Ratio total ranking has improved so far during the Q3 2026 to 1487, from total ranking in the second quarter 2026 at 1892.

Explain Quick Ratio?
How much Cash & cash equivalents VRTX�s has?
What are VRTX�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/VRTX/financial-strength

https://api.csimarket.com/api/v1/companies/VRTX/fundamentals

https://api.csimarket.com/api/v1/companies/VRTX/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

VRTX Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	11.73 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	0.26 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	1.26	Subscribe	Subscribe	Subscribe	Subscribe
VRTX's Total Ranking	# 1487	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	26.98 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-19.73 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 334
Healthcare Sector	# 594
Overall Market	# 1780

Quick Ratio Statistics
High	Average	Low
6.83	3.14	1.26
(Jun 30 2012)		(Sep 30 2026)

Financial Statements
Vertex Pharmaceuticals Inc's Current Liabilities	$ 5,000 Millions	Visit VRTX's Balance sheet
Vertex Pharmaceuticals Inc's Cash & cash equivalent	$ 6,303 Millions	Visit VRTX's Balance sheet
Source of VRTX's Sales		Visit VRTX's Sales by Geography

Cumulative Vertex Pharmaceuticals Inc's Quick Ratio

VRTX's Quick Ratio for the trailling 12 Months

VRTX Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	4.5 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	12.1 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	1.68	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 1098	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	3.25 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	0.06 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to VRTX Financial Strength Comparisons >> Go to Compare VRTX Quick Ratio to its Competitors

On the trailing twelve months basis Due to growth in Current Liabilities in the Q3 2026 to $5,000.30 millions, cumulative Quick Ratio decreased to 1.68 below the Vertex Pharmaceuticals Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 434 other companies have achieved higher Quick Ratio than Vertex Pharmaceuticals Inc. While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending second quarter 2026 at 3913.

Explain Quick Ratio?
How much Cash & cash equivalents VRTX�s has?
What are VRTX�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 435
Healthcare Sector	# 889
Within the Market	#

trailing twelve months Quick Ratio Statistics
High	Average	Low
3.57	2	1.05
(Dec 31 2022)		(Dec 31 2011)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Xilio Therapeutics Inc	3.47	$ 122.182 Millions	$ 35.258 Millions
Corbus Pharmaceuticals Holdings Inc	3.30	$ 115.337 Millions	$ 34.967 Millions
Maia Biotechnology Inc	3.30	$ 21.339 Millions	$ 6.474 Millions
Cytokinetics Incorporated	3.20	$ 1,130.021 Millions	$ 353.419 Millions
Elicio Therapeutics Inc	3.11	$ 30.900 Millions	$ 9.930 Millions
Harmony Biosciences Holdings inc	3.02	$ 771.138 Millions	$ 254.981 Millions
Phio Pharmaceuticals Corp	2.96	$ 10.609 Millions	$ 3.583 Millions
Zevra Therapeutics Inc	2.95	$ 122.148 Millions	$ 41.369 Millions
Nextcure Inc	2.95	$ 8.728 Millions	$ 2.960 Millions
Pyxis Oncology Inc	2.79	$ 55.572 Millions	$ 19.942 Millions
Zenas Biopharma Inc	2.78	$ 177.778 Millions	$ 64.043 Millions
Ptc Therapeutics inc	2.74	$ 2,127.918 Millions	$ 776.076 Millions
Annexon Inc	2.72	$ 102.389 Millions	$ 37.660 Millions
Turn Therapeutics Inc	2.71	$ 9.433 Millions	$ 3.479 Millions
Beone Medicines Ltd	2.67	$ 5,955.905 Millions	$ 2,233.923 Millions
Biohaven Ltd	2.57	$ 161.125 Millions	$ 62.767 Millions
Ironwood Pharmaceuticals inc	2.49	$ 86.376 Millions	$ 34.733 Millions
Azitra Inc	2.44	$ 3.751 Millions	$ 1.540 Millions
Tg Therapeutics Inc	2.43	$ 632.004 Millions	$ 260.526 Millions
Adc Therapeutics Sa	2.42	$ 189.204 Millions	$ 78.125 Millions
Dermata Therapeutics Inc	2.40	$ 4.822 Millions	$ 2.012 Millions
Opko Health Inc	2.37	$ 384.036 Millions	$ 162.356 Millions
Pacira Biosciences inc	2.31	$ 295.577 Millions	$ 128.209 Millions
Dogwood Therapeutics inc	2.28	$ 4.948 Millions	$ 2.174 Millions
Ardelyx inc	2.23	$ 285.338 Millions	$ 127.805 Millions
Schrodinger Inc	2.20	$ 366.358 Millions	$ 166.292 Millions
Stoke Therapeutics Inc	2.19	$ 107.271 Millions	$ 48.977 Millions
Quantum Cyber N v	2.17	$ 5.032 Millions	$ 2.319 Millions
Maravai Lifesciences Holdings Inc	2.14	$ 73.023 Millions	$ 34.160 Millions
Ernexa Therapeutics Inc	2.13	$ 5.575 Millions	$ 2.614 Millions

Date modified: 2026-11-05T14:31:09+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.